HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
INSIDE INDUSTRY
University of Illinois licenses novel anti-cancer therapies to StemPar Sciences
StemPar Sciences, Inc., the University of Illinois at Urbana-Champaign (Illinois), and the University of Texas Southwestern Medical Center (UTSW) have entered into a license agreement through which StemPar Sciences plans to develop cancer therapeutics based on compounds designed by Professor Paul Hergenrother of the Department of Chemistry at the University of Illinois at Urbana-Champaign, and Professor David Boothman, the Robert B. and Virginia Payne Professor in Oncology and Associate Director for Translation Research at UTSW.

The quinone-based compounds exhibited potent anti-cancer activity by inducing programed necrosis, meaning they activate the molecular pathway that causes the premature death of cancerous cells and tissue. The potency and selectivity of these new compounds rival commonly used chemotherapy agents by targeting solid tumors that have elevated levels of the enzyme NAD(P)H:quinone oxioreductase 1 (NQO1). Research indicates that the compounds are able to target a range of solid tumors that are considered difficult to treat, including pancreatic and lung cancers. Furthermore, research suggests that this new class of quinone-based compounds express greater potency than other molecules in the same class, such as β-lapachone. These findings, published in the journal Cancer Research, have shown great promise in pre-clinical testing in mice.

“We view this exclusive worldwide license as an important part of our growing cancer metabolism IP estate,” said StemPar CEO Barry Sherman, MD. “Indeed, this intellectual property has the potential to become a vital ingredient in the quest to develop novel cancer medicines based on the science of cancer metabolism.”

“We are proud to partner with StemPar Sciences to advance this promising research into new cancer therapies,” said Jen Rice, Technology Manager at Illinois’ Office of Technology Management. “We believe the alliance leverages our complementary strengths and will accelerate the development of powerful new therapeutics.”

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy